Cancer Family
Carcinoma
CI-CAN-00000114Explore in graph →
7,369 active trials118 approved drugs1,149 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000114Explore in graph →
Clinical trials
25,729 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3,405)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06707025 | The Expression of CD24 "do-not-eat-me" Signal in Cholangiocarcinoma(CD24CCA) | active not recruiting | — | 50 | Hadassah Medical OrganizationOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT04632433 | Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in Cutaneaous Squamous Cell Carcinoma | active not recruiting | Phase 2 | 25 | Fondazione Melanoma OnlusOTHER | 1 | Mar 13, 2025 |
| clinicaltrials |
| NCT05844150 | A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC | active not recruiting | Phase 2 | 50 | Biotheus Inc.INDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT04246203 | Prognostic Role of Circulating Tumor DNA in Resectable Pancreatic Cancer(PROJECTION) | active not recruiting | — | 200 | Ludwig-Maximilians - University of MunichOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT05918133 | A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC | active not recruiting | Phase 1 / Phase 2 | 42 | Biotheus Inc.INDUSTRY | 1 | Mar 11, 2025 | clinicaltrials |
| NCT06868758 | Predictive Value of Tumor Vascular Normalization Scoring in HER-2 Positive Breast Cancer | active not recruiting | — | 50 | Chongqing General HospitalOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT06863818 | Overcoming Resistance to EGFR Neutralization by Combination of Monoclonal Antibodies and Novel Cancer Drugs | active not recruiting | — | 30 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT04223024 | Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma | active not recruiting | Phase 2 | 246 | Sun Yat-sen UniversityOTHER | 1 | Mar 5, 2025 | clinicaltrials |
| NCT04807192 | CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Cancer (TNBC) | active not recruiting | Phase 2 | 40 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06748495 | Real-world First-line Serplulimab-based Immunochemotherapy for Extensive-stage Small Cell Lung Cancer | active not recruiting | — | 600 | Hunan Cancer HospitalOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06239155 | A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 51 | Ascentawits Pharmaceuticals, LtdINDUSTRY | 1 | Feb 25, 2025 | clinicaltrials |
| NCT02202772 | Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder(CGC) | active not recruiting | Phase 1 / Phase 2 | 51 | Guarionex J. DecastroOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT04165330 | Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 56 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT03822494 | CyberKnife Dose Escalation Prostate Cancer Trial(CK-DESPOT) | active not recruiting | N/A | 100 | Crozer-Keystone Health SystemOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT04344158 | A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) | active not recruiting | Phase 3 | 648 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Feb 20, 2025 | clinicaltrials |
| NCT05917860 | Neoadjuvant ADT with TULSA in the Treatment of Intermediate Risk Prostate Cancer(NeoADT-TULSA) | active not recruiting | Phase 1 | 15 | Turku University HospitalOTHER_GOV | 1 | Feb 17, 2025 | clinicaltrials |
| NCT06827145 | Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC | active not recruiting | Phase 2 | 30 | National Cancer Center, ChinaOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT06828718 | The Neoadjuvant Treatment Modalities in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (NEO-EC）(NEO-EC) | active not recruiting | — | 1,000 | Hebei Medical University Fourth HospitalOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT04001543 | Efficacy of an Oral Immunomodulatory Nutrient on Survival During Postoperative Concomitant Chemoradiotherapy in Head and Neck Cancer(SIMPA01) | active not recruiting | N/A | 27 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT05880472 | Percutaneous Holmium Injection in Pancreatic Cancer(SLOTH-2a) | active not recruiting | N/A | 6 | Radboud University Medical CenterOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT02176902 | Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer | active not recruiting | N/A | 107 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT02859038 | Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY) | active not recruiting | Phase 3 | 489 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 2 | Feb 10, 2025 | clinicaltrials |
| NCT05032040 | A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies | active not recruiting | Phase 2 | 170 | Xencor, Inc.INDUSTRY | 1 | Feb 7, 2025 | clinicaltrials |
| NCT05383079 | Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer(AlphaBet) | active not recruiting | Phase 1 / Phase 2 | 36 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT05586061 | First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer(RCTS) | active not recruiting | Phase 2 | 55 | Qilu Hospital of Shandong UniversityOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06815172 | PARA (Pancreatic Adenocarcinoma Etiology: Role of Asbestos) Study of Risk Factors for Exocrine Pancreatic Neoplasms.(PARA) | active not recruiting | — | 500 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT01973179 | Re-irradiation of Recurrent Head and Neck Cancer(ReKo) | active not recruiting | — | 50 | Technische Universität DresdenOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT06808113 | Circulating and Molecular Markers Involved in the Processes of Cachexia, Anorexia and Sarcopenia in Patients With NSCLC(SARCLUNG) | active not recruiting | — | 40 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT03212404 | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | active not recruiting | Phase 1 | 272 | Checkpoint Therapeutics, Inc.INDUSTRY | 9 | Feb 3, 2025 | clinicaltrials |
| NCT06805084 | Transcripts with Retained H/ACA Box SnoRNA Sequences As Biomarkers for Estrogen Dependence in Lum-B Breast Carcinomas(H/ACA-ER) | active not recruiting | — | 80 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Feb 3, 2025 | clinicaltrials |
| NCT01644669 | Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System® | active not recruiting | N/A | 1,200 | Xoft, Inc.INDUSTRY | 3 | Jan 31, 2025 | clinicaltrials |
| NCT02872025 | Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS) | active not recruiting | Early Phase 1 | 42 | Laura EssermanOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT03944772 | Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)(ORCHARD) | active not recruiting | Phase 2 | 247 | AstraZenecaINDUSTRY | 9 | Jan 30, 2025 | clinicaltrials |
| NCT04597671 | Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28)(NVALT28) | active not recruiting | Phase 3 | 170 | Association NVALT StudiesOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT04625270 | A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation(RAMP 201) | active not recruiting | Phase 2 | 225 | Verastem, Inc.INDUSTRY | 7 | Jan 29, 2025 | clinicaltrials |
| NCT03695952 | A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors | active not recruiting | — | 100 | Asan Medical CenterOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT04308174 | Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer(DEBATE) | active not recruiting | Phase 2 | 45 | Asan Medical CenterOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT04986930 | mFOLFIRINOX With or Without Stereotactic Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma(SABER) | active not recruiting | Phase 2 | 92 | Asan Medical CenterOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT04050436 | Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer(CERPASS) | active not recruiting | Phase 2 | 231 | Replimune, Inc.INDUSTRY | 10 | Jan 27, 2025 | clinicaltrials |
| NCT06794957 | A Study of AL8326 in Non-Small Cell Lung Cancer | active not recruiting | Phase 1 | 158 | Advenchen Laboratories, LLCINDUSTRY | 1 | Jan 27, 2025 | clinicaltrials |
| NCT06790238 | POWER AUDIT, Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol After Gastric Surgery (POWER 4 + 3)(POWER 4 + 3) | active not recruiting | — | 350 | Grupo Español de Rehabilitación MultimodalOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT05587374 | Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)(GEMSTONE) | active not recruiting | Phase 3 | 490 | Sun Yat-sen UniversityOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT05202860 | Impact of Human Papillomavirus (HPV) Vaccination on Burden of Disease in Patients with Actinic Keratosis(VAXAK) | active not recruiting | Phase 2 | 70 | Merete HaedersdalOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT05932836 | An Organoid-on-chips Technique Based on Biopsy Samples and Its Efficacy in Predicting the Response to HAI in HCC | active not recruiting | — | 165 | Xiangya Hospital of Central South UniversityOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT03881605 | MRI Screening Versus SYMptom-directed Surveillance for Brain Metastases Among Patients with Triple Negative or HER2+ MBC(SYMPToM) | active not recruiting | N/A | 50 | Sunnybrook Health Sciences CentreOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06782698 | Home-Based Exercise Program During Neoadjuvant Treatment to Improve Fatigue and Quality of Life in Early HER2-Positive and Triple-Negative Breast Cancer Patients(HoPEx-Breast) | active not recruiting | N/A | 50 | Centro Hospitalar Universitário de Santo AntónioOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT03546361 | CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer | active not recruiting | Phase 1 | 24 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT03840421 | GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 468 | Sun Yat-sen UniversityOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06770699 | Tertiary Lymphoid Structures in Nasopharyngeal Carcinoma | active not recruiting | — | 260 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT04440735 | A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 125 | Kahr MedicalINDUSTRY | 1 | Jan 9, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Mar 14, 2025source: clinicaltrials